Auswahl aktuell laufender klinischer Pharma-Studien am NCRC

Studien zur Multiplen Sklerose / MOGAD:

Titel

  NCT-Nummer

Rekrutierungsstatus

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)

  NCT04411641 aktiv
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)

  NCT04458051 aktiv
WN43194 Satralizumab phase iii (Meteoroid)

   in Vorbereitung
Study MOG001 (Parexel 247511) phase iii (CosMOG)
   in Vorbereitung

 

Studien zur Myasthenia gravis:

Titel

  NCT-Nummer

Rekrutierungsstatus

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis 

  NCT03920293 aktiv
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

  NCT04818671 aktiv
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis

  NCT04951622 in Vorbereitung
A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis   NCT04980495 in Vorbereitung
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

  NCT05218096 in Vorbereitung

 

Studien zur chronisch-inflammatorisch demyelinisierenden Polyneuropathie (CIDP):

Titel

  NCT-Nummer

  Rekrutierungsstatus

A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)

  NCT04281472   aktiv
Gamunex® 10% Use in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) in clinical Routine:
 Observational study to assess Individualized Treatment Decisions (I-GUIDE)
  Sponsor-Reg.GPN-001   aktiv